MA32898B1 - Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone - Google Patents

Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone

Info

Publication number
MA32898B1
MA32898B1 MA33939A MA33939A MA32898B1 MA 32898 B1 MA32898 B1 MA 32898B1 MA 33939 A MA33939 A MA 33939A MA 33939 A MA33939 A MA 33939A MA 32898 B1 MA32898 B1 MA 32898B1
Authority
MA
Morocco
Prior art keywords
receptor
arylmethylbenzoquinazolinone
positive allosteric
allosteric modulators
compounds
Prior art date
Application number
MA33939A
Other languages
Arabic (ar)
English (en)
Inventor
Scott D Kuduk
Douglas C Beshore
Marco Christina Ng Di
Thomas J Greshock
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA32898B1 publication Critical patent/MA32898B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/19—Acids containing three or more carbon atoms
    • C07C53/21—Acids containing three or more carbon atoms containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention se rapporte à des composés de type benzoquinazolinone de formule (I) qui sont des modulateurs allostériques positifs du récepteur M1 et qui sont utiles pour le traitement de maladies dans lequel le récepteur M1 est mis en jeu, tel que la maladie d'Alzheimer, la schizophrénie, la douleur ou les troubles du sommeil. L'invention porte également sur des compositions pharmaceutiques comprenant les composés et sur l'utilisation des composés et des compositions pour le traitement de maladies médiées par le récepteur M1.
MA33939A 2008-11-20 2011-06-13 Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone MA32898B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19974008P 2008-11-20 2008-11-20
PCT/US2009/065060 WO2010059773A1 (fr) 2008-11-20 2009-11-19 Modulateurs allostériques positifs du récepteur m1 d’arylméthylbenzoquinazolinone

Publications (1)

Publication Number Publication Date
MA32898B1 true MA32898B1 (fr) 2011-12-01

Family

ID=41565956

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33939A MA32898B1 (fr) 2008-11-20 2011-06-13 Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone

Country Status (36)

Country Link
US (4) US8557832B2 (fr)
EP (1) EP2358686B1 (fr)
JP (1) JP5102397B2 (fr)
KR (1) KR101305590B1 (fr)
CN (1) CN102292323B (fr)
BR (1) BRPI0921924A2 (fr)
CA (1) CA2743562C (fr)
CO (1) CO6361928A2 (fr)
CR (1) CR20110268A (fr)
CY (1) CY1113665T1 (fr)
DK (1) DK2358686T3 (fr)
DO (1) DOP2011000135A (fr)
EA (1) EA019098B1 (fr)
EC (1) ECSP11011066A (fr)
ES (1) ES2393694T3 (fr)
GE (1) GEP20156348B (fr)
GT (1) GT201100127A (fr)
HN (1) HN2011001358A (fr)
HR (1) HRP20120992T1 (fr)
IL (1) IL212573A (fr)
MA (1) MA32898B1 (fr)
MX (1) MX2011005284A (fr)
MY (1) MY162502A (fr)
NI (1) NI201100100A (fr)
NZ (1) NZ592961A (fr)
PE (1) PE20120031A1 (fr)
PL (1) PL2358686T3 (fr)
PT (1) PT2358686E (fr)
RS (1) RS52528B (fr)
SG (1) SG171769A1 (fr)
SI (1) SI2358686T1 (fr)
SV (1) SV2011003912A (fr)
TN (1) TN2011000209A1 (fr)
UA (1) UA100459C2 (fr)
WO (1) WO2010059773A1 (fr)
ZA (1) ZA201103612B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2915812A1 (fr) * 2009-08-31 2015-09-09 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur m1 pyranyle d'arylméthylbenzoquinazolinone
US8895580B2 (en) 2009-10-21 2014-11-25 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone M1 receptor positive allosteric modulators
WO2011075371A1 (fr) * 2009-12-14 2011-06-23 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs des récepteurs m1 de pyridoquinazolinone
PT2512243E (pt) 2009-12-17 2016-06-08 Merck Sharp & Dohme Moduladores alostéricos positivos de recetor de quinolina amida m1
EP2515656B1 (fr) * 2009-12-21 2014-08-06 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur m1 à base d'aminobenzoquinazolinone
EP2582241B1 (fr) * 2010-06-15 2016-04-06 Merck Sharp & Dohme Corp. Compposés de phénanthrolinone fusionnés hétérocycliques utiles comme modulateurs allostériques positifs du récepteur m1
US8697690B2 (en) 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
US8664234B2 (en) * 2010-10-04 2014-03-04 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators
WO2012158473A1 (fr) 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur m1 au n-méthyl tétrahydro-quinoline
WO2013024006A1 (fr) 2011-08-12 2013-02-21 Basf Se Composés d'anthranilamide et leur utilisation en tant que pesticides
JP2014522873A (ja) 2011-08-12 2014-09-08 ビーエーエスエフ ソシエタス・ヨーロピア アントラニルアミド化合物および殺虫剤としてのその使用
WO2013097052A1 (fr) 2011-12-30 2013-07-04 Abbott Laboratories Inhibiteurs de bromodomaine
IN2012DE00083A (fr) * 2012-01-10 2015-05-01 Council Scient Ind Res
WO2013129622A1 (fr) 2012-03-02 2013-09-06 武田薬品工業株式会社 Composé hétérocyclique et son utilisation
EP2921480B1 (fr) 2012-11-19 2017-10-11 Takeda Pharmaceutical Company Limited Composé hétérocyclique contenant de l'azote
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
CN106232572B (zh) * 2014-04-17 2018-11-13 住友化学株式会社 硝基化合物的制造方法
CA2978214A1 (fr) * 2015-03-06 2016-09-15 Chase Pharmaceuticals Corporation Combinaison contenant un anticholinergique peripherique et un agoniste muscarinique
CA2988572A1 (fr) 2015-06-26 2016-12-29 Takeda Pharmaceutical Company Limited Derives de 2,3-dihydro-4 h-1,3-benzoxazin-4-one comme modulateurs du recepteur m1 muscarinique cholinergique
CA2996717A1 (fr) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du systeme nerveux central
WO2017058689A1 (fr) * 2015-09-30 2017-04-06 Merck Sharp & Dohme Corp. Formes cristallines d'un modulateur allostérique positif du récepteur m1
US10308633B2 (en) 2015-09-30 2019-06-04 Merck Sharp & Dohme Corp. Process for making M1 receptor positive allosteric modulators
JP6787913B2 (ja) * 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
PT3442972T (pt) 2016-04-15 2020-05-29 Abbvie Inc Inibidores de bromodomínio
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018069841A1 (fr) * 2016-10-14 2018-04-19 Pi Industries Ltd Dérivés de phénylamine 4-substitués et leur utilisation pour protéger des cultures par lutte contre des micro-organismes phytopathogènes indésirables
WO2018083051A1 (fr) 2016-11-01 2018-05-11 F. Hoffmann-La Roche Ag 1,3-dihydro -1,4-benzodiazépine-2-thiones pour le traitement de maladies liées au snc
WO2018212312A1 (fr) 2017-05-19 2018-11-22 武田薬品工業株式会社 Procédé de criblage
WO2020067455A1 (fr) 2018-09-28 2020-04-02 武田薬品工業株式会社 Composé hétérocyclique
CN117043302A (zh) 2021-03-18 2023-11-10 默克专利有限公司 用于有机电致发光器件的杂芳族化合物
WO2023114224A1 (fr) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combinaison de modulateurs positifs du récepteur muscarinique et de modulateurs allostériques positifs de nmda
WO2026051746A1 (fr) * 2024-09-06 2026-03-12 四川科伦药物研究院有限公司 Composé, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3071830B2 (ja) * 1995-10-02 2000-07-31 エフ・ホフマン−ラ ロシュ アーゲー ５ｈｔ２ｃ受容体アンタゴニストとしてのピリミジン誘導体
EP0946523A1 (fr) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Derives polycyclique fondus de 2-aminopyrimidine, leur preparation et leur utilisation comme inhibiteurs de proteine tyrosine-kinase
PT1122253E (pt) 1998-10-16 2005-11-30 Sumitomo Pharma Derivados de quinazolinona
JP2005089298A (ja) * 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
WO2004073639A2 (fr) * 2003-02-19 2004-09-02 Merck & Co. Inc. Traitement de la psychose avec un activateur ectopique du recepteur m1 muscarinique
DE602006010540D1 (de) * 2005-05-04 2009-12-31 Hoffmann La Roche (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor
JP2009542663A (ja) 2006-06-28 2009-12-03 メルク エンド カムパニー インコーポレーテッド ベンジル置換キノロンｍ１受容体ポジティブアロステリックモジュレーター
US8664234B2 (en) * 2010-10-04 2014-03-04 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
US20160229813A1 (en) 2016-08-11
CN102292323A (zh) 2011-12-21
PL2358686T3 (pl) 2013-02-28
JP5102397B2 (ja) 2012-12-19
UA100459C2 (en) 2012-12-25
GEP20156348B (en) 2015-08-25
SI2358686T1 (sl) 2013-05-31
US20150031713A1 (en) 2015-01-29
ECSP11011066A (es) 2011-06-30
CR20110268A (es) 2011-07-01
DK2358686T3 (da) 2013-01-07
EP2358686B1 (fr) 2012-09-26
CN102292323B (zh) 2014-12-24
SV2011003912A (es) 2011-10-13
KR20110073596A (ko) 2011-06-29
IL212573A (en) 2015-01-29
EA019098B1 (ru) 2014-01-30
EP2358686A1 (fr) 2011-08-24
JP2012509343A (ja) 2012-04-19
MX2011005284A (es) 2011-06-17
NI201100100A (es) 2011-09-12
BRPI0921924A2 (pt) 2015-12-29
KR101305590B1 (ko) 2013-09-09
GT201100127A (es) 2014-02-10
EA201170705A1 (ru) 2011-12-30
US8883810B2 (en) 2014-11-11
CA2743562A1 (fr) 2010-05-27
US20140005182A1 (en) 2014-01-02
ES2393694T3 (es) 2012-12-27
US20110224198A1 (en) 2011-09-15
US8557832B2 (en) 2013-10-15
HN2011001358A (es) 2014-03-03
AU2009316578A1 (en) 2011-06-23
CY1113665T1 (el) 2016-06-22
NZ592961A (en) 2012-09-28
HK1154587A1 (en) 2012-04-27
HRP20120992T1 (hr) 2012-12-31
MY162502A (en) 2017-06-15
ZA201103612B (en) 2012-01-25
WO2010059773A1 (fr) 2010-05-27
CO6361928A2 (es) 2012-01-20
SG171769A1 (en) 2011-07-28
CA2743562C (fr) 2014-03-18
DOP2011000135A (es) 2011-07-31
RS52528B (sr) 2013-04-30
TN2011000209A1 (en) 2012-12-17
PE20120031A1 (es) 2012-02-05
US9708273B2 (en) 2017-07-18
IL212573A0 (en) 2011-06-30
PT2358686E (pt) 2012-12-06

Similar Documents

Publication Publication Date Title
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
EP2582676A4 (fr) Modulateurs allostériques positifs du récepteur m1 de l'amide tétrahydroquinoline
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
NZ605431A (en) D2 antagonists, methods of synthesis and methods of use
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
WO2009117283A3 (fr) Modulateurs allostériques positifs du récepteur m1 de la quinolizidine
WO2009134668A3 (fr) Modulateurs allostériques positifs pour le récepteur m1 de 4-oxo-1,4-dihydroquinoléine
ATE525370T1 (de) Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten
JO2919B1 (en) Aryl methyl benzocoinazolinone M1 positive allosteric modulation receptor